Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: A phase II study of the Gruppo Oncologico Italia Meridionale

Lung Cancer

Volumn 38, Issue 1, 2002, Pages 79-84

  Galetta, Domenico ^a   Gebbia, Vittorio ^b,d   Giotta, Francesco ^a   Durini, Ernesto ^c   Romito, Sante ^e   Borsellino, Nicola ^d   Cazzato, Carlo ^b   Pezzella, Giuseppe ^f   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c 'G Panico' Hospital of Tricase   (Italy)

^d LA MADDALENA CANCER CENTER   (Italy)

^e 'Cardarelli' Hospital   (Italy)

^f 'SS Annunziata' Hospital   (Italy)

Author keywords

Docetaxel; Gemcitabine; Non small cell lung cancer; Phase II study

Indexed keywords

DOCETAXEL; GEMCITABINE; GROWTH FACTOR; STEROID;

ADENOCARCINOMA; ADULT; AGE; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DISEASE COURSE; DOSE CALCULATION; DRUG ACTIVITY; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; GENDER; HEART FUNCTION; HEMATOLOGY; HISTOLOGY; HUMAN; INFORMED CONSENT; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TIME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COST CONTROL; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG COSTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL; TAXOIDS; TREATMENT OUTCOME;

EID: 0036803652     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00174-5     Document Type: Article

References (31)

1. Ginsberg R.J., Vokes E.E., Raben A. Non small cell lung cancer. De Vita V.T., Hellman S., Rosenberg S.A., Cancer principles and practice of oncology. 5th ed. 1997;858-911 J.B. Lippincott Co, Philadelphia PA.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J. Clin. Oncol. 15:1997;2996-3018.
3. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br. Med. J. 311:1995;899-909.
4. Anderson H., Lund B., Bach F., et al. Single agent activity of weekly gemcitabine in advanced non small cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1821-1826.
5. Abratt R.P., Bezwoda W.R., Falkson G., et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1535-1540.
6. Gatzemeier U., Shepherd F.A., Le Chevalier T., et al. Activity of gemcitabine in patients with non small cell lung cancer: a multicenter extended phase II study. Eur. J. Cancer. 32:1996;243-248.
7. Perng R.P., Chen Y.-M., Liu J.M., et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small cell lung cancer in a phase II randomized study. J. Clin. Oncol. 15:1997;2097-2102.
8. Manegold C., Bergman B., Chemaissani A., et al. Single agent gemcitabine versus cisplatin/etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann. Oncol. 8:1997;525-529.
9. Gueritte-Voegelein F., Guenard D., Lavelle F., et al. Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem. 34:1991;991-998.
10. Langer C.J. Advanced non-small cell lung carcinoma: the emerging role of docetaxel. Inv. New Drugs. 18:2000;17-28.
11. Cortes J.E., Pazdur R. Docetaxel: review article. J. Clin. Oncol. 13:1995;2643-2655.
12. Shepherd F., Dancey G., Ramlau R., et al. A prospective randomized trial of docetaxel (Taxotere) versus best supportive care in patients with non small cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18:2000;2095-2103.
13. Fossella F., Devore R., Kerr R., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with a platinum containing agent. J. Clin. Oncol. 18:2000;2354-2363.
14. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346:2002;92-98.
15. Douillard J.Y., Lerouge D., Monnier A., et al. Combined paclitaxel and gemcitabine as first-line treatment in metastatic non small-cell lung cancer: a multicentre phase II study. Br. J. Cancer. 84:2001;1179-1184.
16. Gridelli C., Cigolari S., Perrone F., et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non small cell lung cancer elderly patients: a phase II data from Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer. 31:2001;277-284.
17. Gridelli C., Frontini L., Perrone F., et al. Gemcitabine plus vinorelbine in advanced non small cell lung cancer: a phase II study of three different doses. Br. J. Cancer. 83:2000;707-714.
18. Bildat S., Harstrick A., Gatzmeier U., et al. Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy in patients with metastatic non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;. abstract 1917.
19. Quantin X., Tranchant B., Pujol J.L., et al. Phase I and pharmacokinetic study of docetaxel (DTX) and gemcitabine (G) in patients with non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;. abstract 720.
20. Jensen N.V., Hansen O., Rose C. Combination of docetaxel and gemcitabine in the treatment of advanced non-small cell lung cancer. Eur. J. Cancer. 35:(Suppl 4):1999;35. abstract 1026.
21. Rigas J.R., Rothenberg M.L., Davis T.H., et al. Phase I clinical and pharmacokinetic study of docetaxel in combination with two gemcitabine infusion schedules. Proc. Am. Soc. Clin. Oncol. 18:(226a):1999;. abstract 870.
22. Isla D., Rosell R., Sanchez J.J., et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 19:2001;1071-1077.
23. Rizvi N.A., Spiridionis C.H., Davis T.H., et al. Docetaxel and gemcitabine combinations in non-small cell lung cancer. Sem. Oncol. 26:(Suppl 16):1999;27-31.
24. Georgoulias V., Kourousis C., Adroulakis N., et al. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine. A multicenter phase II trial. J. Clin. Oncol. 17:1999;914-920.
25. Hejna M., Kornek G.V., Radere M., et al. Treatment of patients with advanced non-small cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor. Cancer. 89:2000;516-522.
26. Rebattu P., Quantin X., Ardiet C., et al. Dose-finding and phase II study of docetaxel in combination with gemcitabine in patient with inoperable non-small cell lung cancer lung. Cancer. 33:2001;277-287.
27. Georgoulias V., Papadakis E., Alexopoulos A., et al. Platinum-based non non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 357:2001;1478-1484.
28. Mountain C. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
29. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatments. Cancer. 47:1981;207-214.
30. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin. Trials. 10:1989;1-10.
31. Collet D. Modelling survival data in medical research. 1994;Chapman and Hale, London.